311 related articles for article (PubMed ID: 22001865)
21. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
[TBL] [Abstract][Full Text] [Related]
22. Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
Am J Physiol Gastrointest Liver Physiol; 2014 Apr; 306(8):G670-6. PubMed ID: 24481602
[TBL] [Abstract][Full Text] [Related]
23. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
24. Chinese children with chronic intrahepatic cholestasis and high γ-glutamyl transpeptidase: clinical features and association with ABCB4 mutations.
Fang LJ; Wang XH; Knisely AS; Yu H; Lu Y; Liu LY; Wang JS
J Pediatr Gastroenterol Nutr; 2012 Aug; 55(2):150-6. PubMed ID: 22343912
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.
Ghonem NS; Ananthanarayanan M; Soroka CJ; Boyer JL
Hepatology; 2014 Mar; 59(3):1030-42. PubMed ID: 24122873
[TBL] [Abstract][Full Text] [Related]
26. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.
Kok T; Bloks VW; Wolters H; Havinga R; Jansen PL; Staels B; Kuipers F
Biochem J; 2003 Feb; 369(Pt 3):539-47. PubMed ID: 12381268
[TBL] [Abstract][Full Text] [Related]
28. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3.
Frider B; Castillo A; Gordo-Gilart R; Bruno A; Amante M; Alvarez L; Mathet V
Ann Hepatol; 2015; 14(5):745-51. PubMed ID: 26256905
[TBL] [Abstract][Full Text] [Related]
29. Hepatic cytochrome P450 deficiency in mouse models for intrahepatic cholestasis predispose to bile salt-induced cholestasis.
Kunne C; de Graaff M; Duijst S; de Waart DR; Oude Elferink RP; Paulusma CC
Lab Invest; 2014 Oct; 94(10):1103-13. PubMed ID: 25068656
[TBL] [Abstract][Full Text] [Related]
30. 1,25-(OH)₂-vitamin D₃ prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model.
Reiter FP; Hohenester S; Nagel JM; Wimmer R; Artmann R; Wottke L; Makeschin MC; Mayr D; Rust C; Trauner M; Denk GU
Biochem Biophys Res Commun; 2015 Apr; 459(2):227-233. PubMed ID: 25712522
[TBL] [Abstract][Full Text] [Related]
31. Ductopenia and cirrhosis in a 32-year-old woman with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature.
Tan YW; Ji HL; Lu ZH; Ge GH; Sun L; Zhou XB; Sheng JH; Gong YH
World J Gastroenterol; 2018 Nov; 24(41):4716-4720. PubMed ID: 30416319
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
33. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
34. Genetic variant c.711A>T in the hepatobiliary phospholipid transporter ABCB4 is associated with significant liver fibrosis.
Smyk W; Weber SN; Hall R; Gruenhage F; Lammert F; Krawczyk M
J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991311
[TBL] [Abstract][Full Text] [Related]
35. Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease.
Li HH; Tyburski JB; Wang YW; Strawn S; Moon BH; Kallakury BV; Gonzalez FJ; Fornace AJ
Alcohol Clin Exp Res; 2014 Jun; 38(6):1520-31. PubMed ID: 24773203
[TBL] [Abstract][Full Text] [Related]
36. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms.
Mezei O; Li Y; Mullen E; Ross-Viola JS; Shay NF
Physiol Genomics; 2006 Jun; 26(1):8-14. PubMed ID: 16507786
[TBL] [Abstract][Full Text] [Related]
37. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice.
Giebeler A; Boekschoten MV; Klein C; Borowiak M; Birchmeier C; Gassler N; Wasmuth HE; Müller M; Trautwein C; Streetz KL
Gastroenterology; 2009 Jul; 137(1):297-308, 308.e1-4. PubMed ID: 19208365
[TBL] [Abstract][Full Text] [Related]
38. ABCB4 Gene Aberrations in Human Liver Disease: An Evolving Spectrum.
Reichert MC; Lammert F
Semin Liver Dis; 2018 Nov; 38(4):299-307. PubMed ID: 30357767
[TBL] [Abstract][Full Text] [Related]
39. Transcription profiling in the liver of undernourished male rat offspring reveals altered lipid metabolism pathways and predisposition to hepatic steatosis.
Lecoutre S; Montel V; Vallez E; Pourpe C; Delmont A; Eury E; Verbanck M; Dickes-Coopman A; Daubersies P; Lesage J; Laborie C; Tailleux A; Staels B; Froguel P; Breton C; Vieau D
Am J Physiol Endocrinol Metab; 2019 Dec; 317(6):E1094-E1107. PubMed ID: 31638854
[TBL] [Abstract][Full Text] [Related]
40. The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.
Huang J; Das SK; Jha P; Al Zoughbi W; Schauer S; Claudel T; Sexl V; Vesely P; Birner-Gruenberger R; Kratky D; Trauner M; Hoefler G
Biochim Biophys Acta; 2013 Oct; 1831(10):1555-65. PubMed ID: 23628473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
